↑ トップへ　← 戻る

 Drug（薬物リスト） ALL | DrugBank 

   e.g. "Sirolimus", "アダリムマブ"    Synonyms (Drugs) were also searched for.

A　B　C　D　E　F　G　H　 I 　J　K　L　M　N　O　P　Q　R　S　T　U　V　W　X　Y　Z　other

130 / 12,172 descriptions found* Show info (disease name, etc.) on mouse-over.
 No.   薬物名（臨床試験情報から抽出）   DrugBank   KEGG DRUG *   KEGG GENES *   KEGG PATHWAY   指定難病告示番号 * 
 1   2-amino-4-(methyl[11c]sulfanyl)butanoic acid   Butyric Acid   D05866   -   -   1件:
34 
 2   [11c]-methionine   Methionine   D00019, D04983   -   -   1件:
34 
 3   [18f]-flt-pet/ct scans   -   -   -   -   1件:
34 
 4   Acetaminophen   Acetaminophen   D00217   2件: PTGS1, PTGS2   1件: Arachidonic acid metabolism   11件:
13,
34,
35,
46,
49,
51,
70,
86,
231,
256,
271 
 5   Afinitor   Everolimus   D02714   1件: MTOR   4件: Breast cancer, ErbB signaling pathway, Pathways in cancer, mTOR signaling pathway   2件:
34,
158 
 6   Aminolevulinic acid   Aminolevulinic acid   D02908, D07567   -   -   2件:
34,
286 
 7   Amn107   -   -   -   -   2件:
34,
86 
 8   Antigen-specific t cells cart/ctl and dcvac   -   -   -   -   1件:
34 
 9   Ar-42   AR-42   -   -   -   1件:
34 
 10   Aspirin   Acetylsalicylic acid   D00109   2件: PTGS1, PTGS2   1件: Arachidonic acid metabolism   10件:
13,
22,
34,
46,
49,
51,
86,
113,
158,
231 
 11   Axitinib   Axitinib   D03218   3件: FLT1, FLT4, KDR   3件: MAPK signaling pathway, Pathways in cancer, VEGF signaling pathway   1件:
34 
 12   Azd2014   -   -   -   -   1件:
34 
 13   Azd6244   -   -   -   -   1件:
34 
 14   Bevacizumab   Bevacizumab   D06409   1件: VEGFA   3件: Pathways in cancer, Renal cell carcinoma, VEGF signaling pathway   9件:
13,
34,
85,
86,
87,
89,
227,
280,
331 
 15   Bevacizumab (genitical recombination)   Bevacizumab   D06409   1件: VEGFA   3件: Pathways in cancer, Renal cell carcinoma, VEGF signaling pathway   1件:
34 
 16   Binimetinib   Binimetinib   D10604   2件: MAP2K1, MAP2K2   3件: MAPK signaling pathway, Melanoma, Pathways in cancer   1件:
34 
 17   Bony toxicity   -   -   -   -   1件:
34 
 18   Butanoic acid   Butyric Acid   D05866   -   -   3件:
34,
51,
97 
 19   Cabozantinib   Cabozantinib   D10062   9件: FLT1, FLT3, FLT4, KDR, KIT, MET, NTRK2, RET, TEK   5件: MAPK signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Ras signaling pathway, VEGF signaling pathway   1件:
34 
 20   Carboplatin   Carboplatin   D01363   -   -   4件:
28,
34,
60,
85 
 21   Cediranib   Cediranib   D08881   3件: FLT1, FLT4, KDR   3件: MAPK signaling pathway, Pathways in cancer, VEGF signaling pathway   1件:
34 
 22   Cediranib maleate   Cediranib   D08881   3件: FLT1, FLT4, KDR   3件: MAPK signaling pathway, Pathways in cancer, VEGF signaling pathway   1件:
34 
 23   Celecoxib   Celecoxib   D00567   1件: PTGS2   1件: Arachidonic acid metabolism   8件:
2,
3,
34,
46,
70,
89,
161,
271 
 24   Celecoxib (celebrex)   Celecoxib   D00567   1件: PTGS2   1件: Arachidonic acid metabolism   1件:
34 
 25   Cetuximab   Cetuximab   D03455   1件: EGFR   3件: ErbB signaling pathway, MAPK signaling pathway, Pathways in cancer   5件:
34,
51,
86,
89,
331 
 26   Chloride   Chloride ion   -   -   -   17件:
6,
11,
13,
14,
34,
46,
51,
96,
97,
127,
168,
193,
227,
228,
288,
297,
299 
 27   Cholecalciferol   Cholecalciferol   D00188   1件: VDR   2件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption   9件:
13,
19,
34,
46,
49,
96,
97,
298,
299 
 28   Dabrafenib   Dabrafenib   D10064   1件: BRAF   3件: ErbB signaling pathway, MAPK signaling pathway, Pathways in cancer   1件:
34 
 29   Dexmedetomidine   Dexmedetomidine   D00514, D01205   3件: ADRA2A, ADRA2B, ADRA2C   1件: Neuroactive ligand-receptor interaction   11件:
2,
4,
6,
21,
34,
70,
113,
212,
215,
226,
280 
 30   Diclofenac   Diclofenac   D00903, D00904, D07816   2件: PTGS1, PTGS2   1件: Arachidonic acid metabolism   4件:
13,
34,
46,
271 
 31   Diclofenac sodium   Diclofenac   D00903, D00904, D07816   2件: PTGS1, PTGS2   1件: Arachidonic acid metabolism   2件:
34,
46 
 32   Doxorubicin   Doxorubicin   D03899   -   -   5件:
26,
28,
34,
61,
331 
 33   Doxorubicin hydrochloride   Doxorubicin   D03899   -   -   4件:
26,
34,
61,
331 
 34   Etoposide   Etoposide   D00125, D04107   -   -   11件:
11,
13,
14,
26,
28,
34,
60,
65,
85,
164,
331 
 35   Everolimus   Everolimus   D02714   1件: MTOR   4件: Breast cancer, ErbB signaling pathway, Pathways in cancer, mTOR signaling pathway   8件:
34,
67,
89,
96,
137,
157,
158,
277 
 36   Everolimus (rad001)   Everolimus, rad001   D02714   1件: MTOR   4件: Breast cancer, ErbB signaling pathway, Pathways in cancer, mTOR signaling pathway   3件:
34,
89,
158 
 37   Everolimus (rad001) , afinitor®   Everolimus, rad001   D02714   1件: MTOR   4件: Breast cancer, ErbB signaling pathway, Pathways in cancer, mTOR signaling pathway   1件:
34 
 38   Evérolimus   -   -   -   -   1件:
34 
 39   Filgrastim   Filgrastim   D03235   1件: CSF3R   5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer   25件:
2,
6,
13,
25,
26,
28,
34,
35,
40,
41,
42,
45,
46,
49,
51,
60,
62,
65,
96,
113,
164,
283,
284,
285,
331 
 40   Fludeoxyglucose f 18   Fludeoxyglucose F-18   -   -   -   1件:
34 
 41   Gadolinium   Gadolinium   -   -   -   6件:
13,
34,
46,
58,
65,
305 
 42   Gadolinium contrast   Gadolinium   -   -   -   1件:
34 
 43   Gadopentetate   Gadopentetic acid   D01707, D08006   -   -   1件:
34 
 44   Gleevec   Imatinib   D01441, D08066   3件: ABL1, KIT, PDGFRA   3件: Chronic myeloid leukemia, MAPK signaling pathway, Pathways in cancer   1件:
34 
 45   Glivec 100 mg comprimidos recubiertos con película   Imatinib   D01441, D08066   3件: ABL1, KIT, PDGFRA   3件: Chronic myeloid leukemia, MAPK signaling pathway, Pathways in cancer   2件:
34,
86 
 46   Glivec 400 mg comprimidos recubiertos con película   Imatinib   D01441, D08066   3件: ABL1, KIT, PDGFRA   3件: Chronic myeloid leukemia, MAPK signaling pathway, Pathways in cancer   1件:
34 
 47   Icotinib   Icotinib   D11251   1件: EGFR   2件: EGFR tyrosine kinase inhibitor resistance, Pathways in cancer   1件:
34 
 48   Ifosfamide   Ifosfamide   D00343   -   -   1件:
34 
 49   Imatinib   Imatinib   D01441, D08066   3件: ABL1, KIT, PDGFRA   3件: Chronic myeloid leukemia, MAPK signaling pathway, Pathways in cancer   11件:
13,
28,
34,
35,
46,
51,
85,
86,
87,
89,
162 
 50   Imatinib mesylate   Imatinib   D01441, D08066   3件: ABL1, KIT, PDGFRA   3件: Chronic myeloid leukemia, MAPK signaling pathway, Pathways in cancer   5件:
13,
28,
34,
51,
86 
 51   Imiquimod   Imiquimod   D02500   1件: TLR7   1件: Toll-like receptor signaling pathway   1件:
34 
 52   Imiquimod 5% cream   Imiquimod   D02500   1件: TLR7   1件: Toll-like receptor signaling pathway   1件:
34 
 53   Interferon alpha-2b   Interferon alfa-2b   D02745   2件: IFNAR1, IFNAR2   7件: Cytokine-cytokine receptor interaction, Hepatitis C, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Natural killer cell mediated cytotoxicity, Pathways in cancer, Toll-like receptor signaling pathway   1件:
34 
 54   Iodide   Iodide   -   -   -   1件:
34 
 55   Isotonic sodium chloride solution   Chloride ion, Sodium chloride   D02056   -   -   1件:
34 
 56   Lamotrigin   -   -   -   -   2件:
34,
195 
 57   Lamotrigine   Lamotrigine   D00354   1件: SCN1A   1件: Dopaminergic synapse   3件:
13,
34,
114 
 58   Lamotrigine dispers   Lamotrigine   D00354   1件: SCN1A   1件: Dopaminergic synapse   1件:
34 
 59   Lapatinib   Lapatinib   D04024, D08108   2件: EGFR, ERBB2   4件: Breast cancer, ErbB signaling pathway, MAPK signaling pathway, Pathways in cancer   3件:
34,
74,
75 
 60   Lenalidomide   Lenalidomide   D04687   1件: TNF   6件: Apoptosis, Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, NF-kappa B signaling pathway, Natural killer cell mediated cytotoxicity, TNF signaling pathway   7件:
16,
26,
28,
34,
49,
284,
300 
 61   Levulan (5-aminolevulinic acid) photodynamic therapy.   Aminolevulinic acid   D02908, D07567   -   -   1件:
34 
 62   Levulan (5-aminolevulinic acid) uptake.   Aminolevulinic acid   D02908, D07567   -   -   1件:
34 
 63   Lovastatin   Lovastatin   D00359   1件: HMGCR   1件: Terpenoid backbone biosynthesis   10件:
6,
34,
46,
79,
156,
160,
195,
206,
263,
310 
 64   Lovastatin 60 mg   Lovastatin   D00359   1件: HMGCR   1件: Terpenoid backbone biosynthesis   1件:
34 
 65   Lovastatin ™   Lovastatin   D00359   1件: HMGCR   1件: Terpenoid backbone biosynthesis   1件:
34 
 66   Mekinist   Trametinib   D10175   2件: MAP2K1, MAP2K2   4件: ErbB signaling pathway, MAPK signaling pathway, Melanoma, Pathways in cancer   1件:
34 
 67   Methionine   Methionine   D00019, D04983   -   -   6件:
34,
75,
84,
93,
229,
300 
 68   Methotrexate   Methotrexate   D00142, D02115   2件: DHFR, DHFR2   2件: Folate biosynthesis, One carbon pool by folate   33件:
11,
13,
19,
34,
35,
41,
42,
43,
44,
45,
46,
49,
50,
51,
53,
55,
56,
60,
62,
65,
84,
93,
96,
97,
162,
164,
172,
256,
271,
284,
285,
326,
331 
 69   Methylphenidate   Methylphenidate   D01296, D04999   2件: SLC6A2, SLC6A3   2件: Dopaminergic synapse, Synaptic vesicle cycle   7件:
6,
13,
34,
84,
113,
179,
206 
 70   Nexavar   Sorafenib   D06272, D08524   8件: BRAF, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET   7件: ErbB signaling pathway, Hepatocellular carcinoma, MAPK signaling pathway, Pathways in cancer, Renal cell carcinoma, Thyroid cancer, VEGF signaling pathway   1件:
34 
 71   Nexavar (bay 43-9006) (sorafenib)   Sorafenib, bay 43-9006   D06272, D08524   8件: BRAF, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET   7件: ErbB signaling pathway, Hepatocellular carcinoma, MAPK signaling pathway, Pathways in cancer, Renal cell carcinoma, Thyroid cancer, VEGF signaling pathway   1件:
34 
 72   Nilotinib   Nilotinib   D08953   4件: ABL1, KIT, PDGFRA, PDGFRB   4件: Chronic myeloid leukemia, ErbB signaling pathway, MAPK signaling pathway, Pathways in cancer   5件:
6,
8,
34,
51,
86 
 73   Nilotinib hydrochloride monohydrate   Nilotinib   D08953   4件: ABL1, KIT, PDGFRA, PDGFRB   4件: Chronic myeloid leukemia, ErbB signaling pathway, MAPK signaling pathway, Pathways in cancer   1件:
34 
 74   Oncolytic measles virus encoding thyroidal sodium iodide symporter   Iodide, Sodium iodide   D04874, D05328, D05863   -   -   1件:
34 
 75   Pd-0325901   PD-0325901   -   -   -   1件:
34 
 76   Pd-0325901 oral capsule   PD-0325901   -   -   -   1件:
34 
 77   Peg-interferon alpha-2b   Interferon alfa-2b   D02745   2件: IFNAR1, IFNAR2   7件: Cytokine-cytokine receptor interaction, Hepatitis C, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Natural killer cell mediated cytotoxicity, Pathways in cancer, Toll-like receptor signaling pathway   1件:
34 
 78   Pharmacodynamics   -   -   -   -   1件:
34 
 79   Pirfenidone   Pirfenidone   D01583   6件: CCL2, IL10, IL1A, IL1B, IL6, TNF   5件: Cellular senescence, Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, TGF-beta signaling pathway, TNF signaling pathway   10件:
34,
46,
50,
51,
58,
84,
85,
164,
222,
228 
 80   Plx3397   -   -   -   -   2件:
34,
46 
 81   Pomalidomide   Pomalidomide   D08976   2件: IL6, TNF   6件: Apoptosis, Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway   6件:
28,
34,
51,
85,
227,
331 
 82   Propofol   Propofol   D00549   16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ   2件: GABAergic synapse, Neuroactive ligand-receptor interaction   8件:
6,
21,
22,
34,
46,
84,
98,
296 
 83   Ptc299   PTC299   -   -   -   1件:
34 
 84   Qol assessment, neuropsychological   -   -   -   -   1件:
34 
 85   Rad001   rad001   D02714   1件: MTOR   4件: Breast cancer, ErbB signaling pathway, Pathways in cancer, mTOR signaling pathway   5件:
34,
67,
89,
96,
158 
 86   Rad001, everolimus   Everolimus, rad001   D02714   1件: MTOR   4件: Breast cancer, ErbB signaling pathway, Pathways in cancer, mTOR signaling pathway   1件:
34 
 87   Rad001: everolimus   Everolimus, rad001   D02714   1件: MTOR   4件: Breast cancer, ErbB signaling pathway, Pathways in cancer, mTOR signaling pathway   1件:
34 
 88   Radiographic evaluation   -   -   -   -   1件:
34 
 89   Ranibizumab   Ranibizumab   D05697   1件: VEGFA   1件: VEGF signaling pathway   4件:
34,
166,
227,
301 
 90   Rapamycin   Sirolimus   D00753   1件: MTOR   2件: Pathways in cancer, mTOR signaling pathway   16件:
2,
15,
34,
35,
46,
49,
51,
60,
61,
67,
86,
89,
158,
256,
278,
279 
 91   Saline solution   -   -   -   -   4件:
2,
34,
288,
299 
 92   Selumetinib   Selumetinib   D09666   2件: MAP2K1, MAP2K2   2件: ErbB signaling pathway, MAPK signaling pathway   1件:
34 
 93   Selumetinib (azd6244 hyd sulfate) 25mg/m2   Selumetinib, Sulfate ion   D09666   2件: MAP2K1, MAP2K2   2件: ErbB signaling pathway, MAPK signaling pathway   1件:
34 
 94   Selumetinib (azd6244 hyd sulfate) 50mg/dose   Selumetinib, Sulfate ion   D09666   2件: MAP2K1, MAP2K2   2件: ErbB signaling pathway, MAPK signaling pathway   1件:
34 
 95   Selumetinib sulfate   Selumetinib, Sulfate ion   D09666   2件: MAP2K1, MAP2K2   2件: ErbB signaling pathway, MAPK signaling pathway   1件:
34 
 96   Simvastatin   Simvastatin   D00434   1件: HMGCR   1件: Terpenoid backbone biosynthesis   19件:
6,
13,
15,
34,
46,
49,
51,
66,
79,
86,
89,
94,
158,
162,
195,
265,
298,
299,
310 
 97   Simvastatin 20mg/5ml oral suspension   Simvastatin   D00434   1件: HMGCR   1件: Terpenoid backbone biosynthesis   1件:
34 
 98   Sirolimus   Sirolimus   D00753   1件: MTOR   2件: Pathways in cancer, mTOR signaling pathway   30件:
13,
17,
34,
35,
36,
46,
51,
60,
62,
63,
65,
66,
67,
85,
89,
96,
98,
137,
157,
158,
192,
222,
277,
278,
279,
280,
281,
283,
285,
331 
 99   Skincerity   -   -   -   -   2件:
34,
158 
 100   Skincerity plus sirolimus/rapamycin   Sirolimus   D00753   1件: MTOR   2件: Pathways in cancer, mTOR signaling pathway   2件:
34,
158 
 101   Skinercity plus sirolimus/rapamycin   Sirolimus   D00753   1件: MTOR   2件: Pathways in cancer, mTOR signaling pathway   2件:
34,
158 
 102   Sodium chloride   Chloride ion, Sodium chloride   D02056   -   -   13件:
6,
11,
13,
14,
34,
46,
51,
168,
193,
227,
228,
288,
299 
 103   Sodium iodide   Iodide, Sodium iodide   D04874, D05328, D05863   -   -   1件:
34 
 104   Sorafenib   Sorafenib   D06272, D08524   8件: BRAF, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET   7件: ErbB signaling pathway, Hepatocellular carcinoma, MAPK signaling pathway, Pathways in cancer, Renal cell carcinoma, Thyroid cancer, VEGF signaling pathway   2件:
34,
86 
 105   Sorafenib (as tosylate)   Sorafenib   D06272, D08524   8件: BRAF, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET   7件: ErbB signaling pathway, Hepatocellular carcinoma, MAPK signaling pathway, Pathways in cancer, Renal cell carcinoma, Thyroid cancer, VEGF signaling pathway   1件:
34 
 106   Sulfate   Sulfate ion   -   -   -   22件:
2,
6,
11,
13,
26,
34,
36,
46,
49,
60,
61,
64,
66,
79,
86,
96,
222,
226,
265,
296,
297,
299 
 107   Sunitinib   Sunitinib   D06402, D08552   9件: CSF1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET   3件: MAPK signaling pathway, Pathways in cancer, VEGF signaling pathway   2件:
28,
34 
 108   Sutent®/sunitinib   Sunitinib   D06402, D08552   9件: CSF1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET   3件: MAPK signaling pathway, Pathways in cancer, VEGF signaling pathway   1件:
34 
 109   Tarceva and rapamycin   Sirolimus   D00753   1件: MTOR   2件: Pathways in cancer, mTOR signaling pathway   1件:
34 
 110   Tasigna   Nilotinib   D08953   4件: ABL1, KIT, PDGFRA, PDGFRB   4件: Chronic myeloid leukemia, ErbB signaling pathway, MAPK signaling pathway, Pathways in cancer   2件:
34,
86 
 111   Tasigna 150mg   Nilotinib   D08953   4件: ABL1, KIT, PDGFRA, PDGFRB   4件: Chronic myeloid leukemia, ErbB signaling pathway, MAPK signaling pathway, Pathways in cancer   1件:
34 
 112   Tasigna 200mg   Nilotinib   D08953   4件: ABL1, KIT, PDGFRA, PDGFRB   4件: Chronic myeloid leukemia, ErbB signaling pathway, MAPK signaling pathway, Pathways in cancer   1件:
34 
 113   Temozolomide   Temozolomide   D06067   -   -   1件:
34 
 114   Temozolomide (temodar)   Temozolomide   D06067   -   -   1件:
34 
 115   Temsirolimus   Temsirolimus   D06068   1件: MTOR   3件: ErbB signaling pathway, Pathways in cancer, mTOR signaling pathway   4件:
13,
34,
89,
331 
 116   Tipifarnib   Tipifarnib   D03720   2件: FNTA, FNTB   1件: Terpenoid backbone biosynthesis   1件:
34 
 117   Toxicity, pharmacokinetics   -   -   -   -   1件:
34 
 118   Trametinib   Trametinib   D10175   2件: MAP2K1, MAP2K2   4件: ErbB signaling pathway, MAPK signaling pathway, Melanoma, Pathways in cancer   1件:
34 
 119   Treatment a   -   -   -   -   2件:
34,
46 
 120   Treatment b   -   -   -   -   2件:
34,
46 
 121   Treatment c   -   -   -   -   2件:
34,
46 
 122   Treatment d   -   -   -   -   1件:
34 
 123   Valproic acid   Valproic Acid   D00399   6件: ABAT, CACNA1G, CACNA1H, CACNA1I, GAD1, GAD2   2件: Calcium signaling pathway, GABAergic synapse   10件:
3,
5,
26,
34,
65,
89,
90,
222,
256,
331 
 124   Vinblastine   Vinblastine   D01068, D08675   9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8   1件: Gap junction   1件:
34 
 125   Vinblastine sulfate   Sulfate ion, Vinblastine   D01068, D08675   9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8   1件: Gap junction   1件:
34 
 126   Vinblastine sulphate   Vinblastine   D01068, D08675   9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8   1件: Gap junction   1件:
34 
 127   Vincristine   Vincristine   D02197, D08679   9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8   1件: Gap junction   4件:
26,
34,
61,
331 
 128   Vincristine sulfate   Sulfate ion, Vincristine   D02197, D08679   9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8   1件: Gap junction   3件:
26,
34,
61 
 129   Vincristine sulfate (oncovin)   Sulfate ion, Vincristine   D02197, D08679   9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8   1件: Gap junction   1件:
34 
 130   Votubia   Everolimus   D02714   1件: MTOR   4件: Breast cancer, ErbB signaling pathway, Pathways in cancer, mTOR signaling pathway   2件:
34,
158 

先頭へ